Claris to go it alone in USA
Claris Lifesciences, a leading Indian injectable generic pharmaceuticals maker, has said that, following approval by the US Food and Drug Administration of the corrective actions taken at its plant in Ahmedabad, the company can now manufacture and sell its products in the USA. It can also receive Abbreviated New Drug Application (ANDA) approvals, the company added.
In November 2010, the FDA had issued a warning letter to the company along with an import alert for violation of approved manufacturing norms at the company's Ahmedabad facility and also banned import of products manufactured at the plant to the USA.
Drops deals with Pfizer and others
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze